Logo image of CPIX

CUMBERLAND PHARMACEUTICALS (CPIX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CPIX - US2307701092 - Common Stock

4.68 USD
-0.04 (-0.85%)
Last: 1/13/2026, 8:02:15 PM
Fundamental Rating

3

CPIX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. CPIX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CPIX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • CPIX had positive earnings in the past year.
  • CPIX had a positive operating cash flow in the past year.
  • In the past 5 years CPIX always reported negative net income.
  • CPIX had a positive operating cash flow in 4 of the past 5 years.
CPIX Yearly Net Income VS EBIT VS OCF VS FCFCPIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

  • The Return On Assets of CPIX (-5.05%) is better than 71.58% of its industry peers.
  • CPIX has a Return On Equity of -12.74%. This is in the better half of the industry: CPIX outperforms 70.53% of its industry peers.
Industry RankSector Rank
ROA -5.05%
ROE -12.74%
ROIC N/A
ROA(3y)-7.42%
ROA(5y)-5.97%
ROE(3y)-21.64%
ROE(5y)-16.04%
ROIC(3y)N/A
ROIC(5y)N/A
CPIX Yearly ROA, ROE, ROICCPIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5 -10 -15 -20 -25

1.3 Margins

  • With an excellent Gross Margin value of 84.49%, CPIX belongs to the best of the industry, outperforming 87.37% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CPIX has remained more or less at the same level.
  • CPIX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.04%
CPIX Yearly Profit, Operating, Gross MarginsCPIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

  • CPIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CPIX has been reduced compared to 1 year ago.
  • The number of shares outstanding for CPIX has been reduced compared to 5 years ago.
  • The debt/assets ratio for CPIX is higher compared to a year ago.
CPIX Yearly Shares OutstandingCPIX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
CPIX Yearly Total Debt VS Total AssetsCPIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of 1.08, we must say that CPIX is in the distress zone and has some risk of bankruptcy.
  • CPIX's Altman-Z score of 1.08 is in line compared to the rest of the industry. CPIX outperforms 52.11% of its industry peers.
  • The Debt to FCF ratio of CPIX is 0.79, which is an excellent value as it means it would take CPIX, only 0.79 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 0.79, CPIX belongs to the best of the industry, outperforming 96.32% of the companies in the same industry.
  • CPIX has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
  • CPIX's Debt to Equity ratio of 0.20 is in line compared to the rest of the industry. CPIX outperforms 44.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF 0.79
Altman-Z 1.08
ROIC/WACCN/A
WACC9.06%
CPIX Yearly LT Debt VS Equity VS FCFCPIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 1.23 indicates that CPIX should not have too much problems paying its short term obligations.
  • The Current ratio of CPIX (1.23) is worse than 80.00% of its industry peers.
  • A Quick Ratio of 1.11 indicates that CPIX should not have too much problems paying its short term obligations.
  • The Quick ratio of CPIX (1.11) is worse than 77.37% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.11
CPIX Yearly Current Assets VS Current LiabilitesCPIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

  • CPIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 158.82%, which is quite impressive.
  • CPIX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.21%.
  • CPIX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.95% yearly.
EPS 1Y (TTM)158.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)12.21%
Revenue growth 3Y1.71%
Revenue growth 5Y1.95%
Sales Q2Q%-8.8%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CPIX Yearly Revenue VS EstimatesCPIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CPIX Yearly EPS VS EstimatesCPIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2023 2024 0 0.2 -0.2

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 46.80, which means the current valuation is very expensive for CPIX.
  • CPIX's Price/Earnings ratio is a bit cheaper when compared to the industry. CPIX is cheaper than 76.84% of the companies in the same industry.
  • CPIX is valuated expensively when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 46.8
Fwd PE N/A
CPIX Price Earnings VS Forward Price EarningsCPIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • 75.26% of the companies in the same industry are more expensive than CPIX, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, CPIX is valued cheaper than 91.05% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.5
EV/EBITDA 124.75
CPIX Per share dataCPIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • CPIX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CUMBERLAND PHARMACEUTICALS

NASDAQ:CPIX (1/13/2026, 8:02:15 PM)

4.68

-0.04 (-0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04
Earnings (Next)03-02
Inst Owners22.93%
Inst Owner Change0%
Ins Owners3.53%
Ins Owner Change0.02%
Market Cap70.01M
Revenue(TTM)41.28M
Net Income(TTM)-3.33M
Analysts43.33
Price TargetN/A
Short Float %0.35%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 46.8
Fwd PE N/A
P/S 1.7
P/FCF 10.5
P/OCF 10.24
P/B 2.68
P/tB 6.87
EV/EBITDA 124.75
EPS(TTM)0.1
EY2.14%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.45
FCFY9.53%
OCF(TTM)0.46
OCFY9.76%
SpS2.76
BVpS1.75
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.98
Profitability
Industry RankSector Rank
ROA -5.05%
ROE -12.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.49%
FCFM 16.16%
ROA(3y)-7.42%
ROA(5y)-5.97%
ROE(3y)-21.64%
ROE(5y)-16.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.33%
GM growth 5Y1.04%
F-Score8
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF 0.79
Debt/EBITDA 10.89
Cap/Depr 4.41%
Cap/Sales 0.4%
Interest Coverage N/A
Cash Conversion 1419.63%
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.11
Altman-Z 1.08
F-Score8
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)17.26%
Cap/Depr(5y)20.78%
Cap/Sales(3y)2.19%
Cap/Sales(5y)2.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.21%
Revenue growth 3Y1.71%
Revenue growth 5Y1.95%
Sales Q2Q%-8.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.37%
OCF growth 3YN/A
OCF growth 5YN/A

CUMBERLAND PHARMACEUTICALS / CPIX FAQ

Can you provide the ChartMill fundamental rating for CUMBERLAND PHARMACEUTICALS?

ChartMill assigns a fundamental rating of 3 / 10 to CPIX.


Can you provide the valuation status for CUMBERLAND PHARMACEUTICALS?

ChartMill assigns a valuation rating of 3 / 10 to CUMBERLAND PHARMACEUTICALS (CPIX). This can be considered as Overvalued.


How profitable is CUMBERLAND PHARMACEUTICALS (CPIX) stock?

CUMBERLAND PHARMACEUTICALS (CPIX) has a profitability rating of 3 / 10.


What is the financial health of CUMBERLAND PHARMACEUTICALS (CPIX) stock?

The financial health rating of CUMBERLAND PHARMACEUTICALS (CPIX) is 5 / 10.